Diamyd Medical

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Diamyd Medical AB (Stockholm NASDAQ, First North) is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for diabetes. The company is developing two products.

The company is headquartered in Stockholm, and maintains a manufacturing facility in Umeå.^[1]

External links

Diamyd Medical AB

References

^ "Annual Report 2021/2022" (PDF). Diamyd Medical AB. Retrieved 20 February 2023.

[1] "Annual Report 2021/2022" (PDF). Diamyd Medical AB. Retrieved 20 February 2023.

[1]